FORXIGA

Type: Product

Name: FORXIGA

First reported May 05 2013 - Updated May 05 2013 - 1 reports

Bristol-Myers Has The Future Of Oncology Therapies

Bristol-Myers (NYSE: BMY) recently reported its Q1 2013 financial results with a 27% decline in pharmaceutical revenues towards Q1 2012, but with a 10% increase excluding Avapro and Plavix. The Eliquis launch has also been slightly disappointing, with ... [Published Seeking Alpha - May 05 2013]

Entities: Bristol-Myers Squibb Company, Ipilimumab, Skin Cancer, Patient

First reported Apr 29 2013 - Updated Apr 30 2013 - 1 reports

Merck & Co Inc

Merck Joins Pfizer to Develop Type 2 Diabetes Drug

On the eve of Phase III trials expected to start later this year, Merck & Co. and Pfizer said today they will team up to develop and commercialize Pfizer’s ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor ... [Published Genetic Engineering News - Apr 29 2013]

Entities: Merck & Co Inc, Pfizer Inc, Diabetes Type II

First reported Apr 26 2013 - Updated Apr 26 2013 - 1 reports

Bristol-Myers Squibb's Management Discusses Q1 2013 Results - Earnings Call Transcript

Bristol-Myers Squibb Company (BMY) Q1 2013 Earnings Conference Call April 25, 2013 10:30 AM ETOperatorGood day and welcome to today’s First Quarter Earnings 2013 Release Conference Call. This call is being recorded. At this time, I would like to turn ... [Published Seeking Alpha - Apr 26 2013]

Entities: John Elicker, ELIQUIS, Abatacept, Bristol-Myers Squibb Company, Onglyza

First reported Apr 24 2013 - Updated Apr 24 2013 - 1 reports

Teva Pharmaceutical Industries Ltd

Brystol-Myers Squibbs Preview: Performance Of New Drugs The Key

Brystol-Myers Squibbs (NYSE:BMY) is scheduled to announce its results for Q1 2013 on April 25. All eyes will be on the performance of its new drugs, which will be the key drivers of revenue growth going forward. The company has started to feel the pressure ... [Published Trefis - Apr 24 2013]

Entities: Drugs, Baraclude, Patent, Teva Pharmaceutical Industries Ltd

First reported Feb 01 2013 - Updated Feb 01 2013 - 2 reports

National Institute for Health & Clinical Excellence

Negative NICE guidance for Roche's Avastin and BMSAstraZeneca's Forxiga

Home » Syndicated Content » Negative NICE guidance for Roche's Avastin and B-MSAstraZeneca's ForxigaUK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has published draft guidance today (February 1) on the use of Swiss ... [Published BioPortfolio - Feb 01 2013]

Entities: National Institute for Health & Clinical Excell..., Avastin, FORXIGA, Roche Holding AG

First reported Feb 01 2013 - Updated Feb 01 2013 - 1 reports

NICE unable to recommend dapagliflozin for type 2 diabetes and requests more information from the manufacturer

In draft guidance published today (1 February), NICE is minded not to recommend dapagliflozin (Forxiga, Brstol-Myers Squibb and Astra Zeneca) in combination therapy for treating type 2 diabetes. ... [Published NICE | National Institute for Health and Clinic ... - Feb 01 2013]

Entities: Dapagliflozin, Diabetes Type II, FORXIGA

First reported Jan 31 2013 - Updated Jan 31 2013 - 1 reports

Bristol-Myers Squibb Company

Bristol-Myers Squibb's revenue falls by 23% on patent expiration

Bristol-Myers Squibb has suffered heavy setback during the fourth quarter ended December 2012 and its revenue declined sharply by 23.2 per cent to $ 4,191 million from $ 5,454 million in the corresponding period of last year following the US patent expiration ... [Published PharmaBiz - Jan 31 2013]

Entities: Bristol-Myers Squibb Company, Avapro, Declination

First reported Dec 07 2012 - Updated Dec 07 2012 - 1 reports

Human medicines European Public Assessment Report (EPAR): Forxiga, dapagliflozin, Revision: 0, Authorised

[Published Pending EC decisions and European Public Assess ... - Dec 07 2012]

Entities: FORXIGA, Dapagliflozin

Quotes

"Ertugliflozin was discovered in Pfizer's Cardiovascular & Metabolic Diseases (CVMED) Research Unit at its Groton laboratories" Pfizer spokewoman Joan Campion said in an email to The Day

Pfizer and Merck partner to develop diabetes drug [Published PredictWallStreet - Apr 30 2013]

"We are pleased to join forces with Merck in the battle against type 2 diabetes and the burden that it poses on global health. Through this collaboration, we believe we can build on Merck's leadership position in diabetes care with the introduction of ertugliflozin, an innovative SGLT2 inhibitor discovered by Pfizer scientists."

Merck And Pfizer Collaborate To Develop New Diabetes Drug [Published MediLexicon - Apr 30 2013]

"Merck continues to build upon our leadership position in the oral treatment of type 2 diabetes through our own research and business development" said Nancy Thornberry, senior vice president and diabetes and endocrinology franchise head, Merck Research Laboratories...

Rival giants team on diabetes as Merck partners with Pfizer on SGLT2 combo [Published FierceBiotech - Apr 29 2013]

More Content

sort by: Date \| Relevance
Bristol-Myers Has The Future Of Oncology Therapies [Published Seeking Alpha - May 05 2013]
Pfizer and Merck partner to develop diabetes drug [Published PredictWallStreet - Apr 30 2013]
Merck And Pfizer Collaborate To Develop New Dia... [Published MediLexicon - Apr 30 2013]
Merck Joins Pfizer to Develop Type 2 Diabetes Drug [Published Genetic Engineering News - Apr 29 2013]
Rival giants team on diabetes as Merck partners... [Published FierceBiotech - Apr 29 2013]
Bristol-Myers Squibb's Management Discusses Q1 ... [Published Seeking Alpha - Apr 26 2013]
Brystol-Myers Squibbs Preview: Performance Of N... [Published Trefis - Apr 24 2013]
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Apr 05 2013]
Negative NICE guidance for Roche's Avastin and ... [Published BioPortfolio - Feb 01 2013]
EUROPEAN EQUITY OPENING HEADLINES INCLUDING: RW... [Published Proactiveinvestors United Kingdom RSS feed - Feb 01 2013]
NICE issues preliminary decision on FORXIGA med... [Published PBR - News - Feb 01 2013]
NICE unable to recommend dapagliflozin for type... [Published NICE \| National Institute for Health and Clinic ... - Feb 01 2013]
Bristol-Myers Squibb's revenue falls by 23% on ... [Published PharmaBiz - Jan 31 2013]
DELÅRSRAPPORT FÖR FJÄRDE KVARTALET OCH JANUARI ... [Published GlobeNewswire: Acquisitions News - Jan 31 2013]
Bristol-Myers Squibb Earnings: Here’s Why Inves... [Published Wall St. Cheat Sheet - Jan 24 2013]
M&A Deal of the Year Nominee Bristol-Myers/Amyl... [Published The IN VIVO Blog - Dec 18 2012]
Human medicines European Public Assessment Repo... [Published Pending EC decisions and European Public Assess ... - Dec 07 2012]